According to our results, a distinguished group of patients who might benefit from possible personalized treatment strategies are those with diagnosed ccRCC with a low or absent expression of INVS, as well as those with a high expression of DVL3 in tumor specimens, which can both be established easily with a simple and inexpensive method. This evidence concerns the gene INVS and neoplasm.